LPTX Leap Therapeutics Inc.

1.62
-0.02  -1%
Previous Close 1.64
Open 1.62
Price To Book 3.95
Market Cap 36061688
Shares 22,260,301
Volume 356,421
Short Ratio
Av. Daily Volume 1,329,186

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data noted 46.7% ORR.
TRX518 in combination with gemcitabine chemotherapy or KEYTRUDA or Opdivo
Advanced solid tumors
Phase 1/2 data ESMO October 2018. 24% ORR.
DKN-01 + KEYTRUDA
Esophagogastric adenocarcinoma
Phase 1/2 data released December 14, 2018 noted 21.3% PR rate.
DKN-01
Biliary tract cancer (BTC)
Phase 1/2 enrolling as of January 2017.
DKN-01
Esophageal cancer
Phase 2 data March 18, 2019 noted 1/21 PRs in combo trial, 1/12 PRs as monotherapy.
DKN-01 and Paclitaxel
Endometrial Cancer
Phase 1/2 trial to be initiated 1Q 2019.
TRX518 and avelumab
Solid tumors

Latest News

  1. Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference
  2. Leap Therapeutics Reports Clinical Update and 2018 Financial Results
  3. Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer
  4. Four Tech Stocks Setting The Pace On Monday
  5. Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer
  6. Leap Therapeutics Inc (LPTX) CEO, President, Chairman Christopher Mirabelli Bought $999,999 of ...
  7. Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities
  8. Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants
  9. Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
  10. 2 Small-Cap Biotech Stocks That Are on My Radar
  11. Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019
  12. Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer
  13. Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer
  14. Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results
  15. Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting
  16. Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress
  17. Leap Therapeutics to Present Data from Study Evaluating DKN-01 in Combination with KEYTRUDA® (pembrolizumab) at the European Society of Medical Oncology 2018 Congress
  18. Leap Therapeutics to Present at Two October Conferences
  19. Leap Therapeutics to Participate in the H.C. Wainwright 20th Annual Global Investment Conference